| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
|
Clin Cancer Res
|
2008
|
1.97
|
|
2
|
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
|
J Clin Oncol
|
2008
|
1.65
|
|
3
|
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
|
Blood
|
2013
|
1.54
|
|
4
|
NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma.
|
Leuk Res
|
2011
|
1.44
|
|
5
|
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
|
J Clin Oncol
|
2009
|
1.14
|
|
6
|
Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution.
|
Eur J Haematol
|
2006
|
1.12
|
|
7
|
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
|
Haematologica
|
2007
|
1.10
|
|
8
|
Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study.
|
Am J Surg Pathol
|
2006
|
1.09
|
|
9
|
Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results.
|
Br J Haematol
|
2012
|
1.03
|
|
10
|
Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
|
Br J Haematol
|
2007
|
1.00
|
|
11
|
Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.
|
Br J Haematol
|
2009
|
0.93
|
|
12
|
Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
|
Eur J Haematol
|
2006
|
0.88
|
|
13
|
Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma.
|
Leuk Res
|
2010
|
0.85
|
|
14
|
Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP.
|
Br J Haematol
|
2012
|
0.85
|
|
15
|
Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease.
|
AIDS
|
2002
|
0.84
|
|
16
|
Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation.
|
Br J Haematol
|
2012
|
0.81
|
|
17
|
Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen.
|
Leuk Lymphoma
|
2009
|
0.81
|
|
18
|
Nodal marginal zone lymphoma in AIDS patients: a casual association?
|
AIDS
|
2002
|
0.76
|
|
19
|
Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain.
|
Med Clin (Barc)
|
2008
|
0.76
|
|
20
|
HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era.
|
AIDS
|
2015
|
0.75
|
|
21
|
[Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients].
|
Med Clin (Barc)
|
2006
|
0.75
|